Endocrinological Approach to the Asymptomatic Primary Hyperparathyroidism

Abstract

Primary hyperparathyroidism (PHPT) diagnosis were increased in recent years due to increase measurement of serum calcium without any signs and symptoms of hypercalcemia. There are different medical or surgical treatment approaches in silent or asymptomatic PHPT. In our summary, we reviewed the endocrinologicaltreatment approaches to the asymptomatic PHPT

Keywords

• Hypercalcemia,asymptomatic hyperparathyroidism,medical treatment

Asemptomatik Primer Hiperparatiroidi Hastalarına Endokrinolojik Yaklaşım

Abstract

Serum kalsiyum düzeyi ölçümünün giderek daha yaygın kullanıldığı günümüzde herhangi bir belirti, bulgu olmaksızın primer hiperparatiroidizm tanısı alan olguların sayısı artmaktadır. Çoğu zaman hiçbir klinik bulgu vermeyen bu hastalığın medikal ve cerrahi tedavi yaklaşımları açısından değişik görüşler yayınlanmaktadır. Bu derlememizde asemptomatik hiperparatiroidizm tanısı konulan hastalara endokrinolojik açıdan tedavi yaklaşımı özetlendi

Keywords

• Hiperkalsemi,asemptomatik hiperparatiroidizm,medikal tedavi

References

1. Wermers RA, Khosla S, Atkinson EJ, Hodgson SF, O'Fallon WM, Melton LJ 3rd: The hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965-1992. Ann Intern Med. 126 (6): 433-40, 1997.
2. Kearns AE, Thompson GB. Medical and surgical management of hyperparathyroidism. Mayo Clin Proc. 77(1):87-91, 2002.
3. Taniegra ED. Hyperparathyroidism. Am Fam Physician. 69(2): 333-39, 2004.
4. Bilezikian JP, Potts JT Jr, Fuleihan Gel- H, Kleerekoper M, Neer R, Peacock M, Rastad J, Silverberg SJ, Udelsman R, Wells SA Jr:Summary statement from a workshop hyperparathyroidism: a perspective for the 21st century. J Bone Miner Res. 17 (Suppl 2):N2- , 2002.
5. Silverberg SJ. Natural history of primary hyperparathyroidism. Endocrinol Metab Clin North Am. 29 (3): 451-64, 2000.
6. Bilezikian JP, Silverberg SJ. Clinical practice. Asymptomatic primary hyperpara- thyroidism. N Engl J Med. 350 (17): 1746- ,2004. fall of primary on asymptomatic primary
7. Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, Schussheim D, Rubin MR, Shaikh AM, Silverberg SJ, Standish TI, Syed Z, Syed ZA: Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 89(7): 3319-25, 2004.
8. Parker CR, Blackwell PJ, Fairbairn KJ, Hosking DJ. Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study. J Clin Endocrinol Metab. 87 (10): 4482-89,2002.

9. Chow CC, Chan WB, Li JK, Chan NN, Chan MH, Ko GT, Lo KW, Cockram CS: Oral alendronate increases bone mineral density in postmenopausal hyperparathyroidism.J Clin Endocrinol Metab. (2):581-87, 2003.
10. Zanchetta JR, Bogado CE: Raloxifene reverses bone loss in postmenopausal women with hyperparathyroidism. J Bone Miner Res. 16(1): 90, 2001.
11. Rubin MR, Lee KH, McMahon DJ, Silverberg SJ: Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal hyperparathyroidism.J Clin Endocrinol Metab. (3):1174-78, 2003.
12. Sajid-Crockett S, Singer FR, Hershman JM: Cinacalcet for the treatment of primary hyperparathyroidism. Metabolism. 57 (4): 517- , 2008. with primary mild asymptomatic primary women with primary